Codiak BioSciences, a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines...
Read More »G-CON PODs Selected for Codiak BioSciences’ engEx™ Exosome Manufacturing Facility
PODs Will Support Clinical Manufacturing for this Novel Therapeutic Modality. G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, announced today that it has been selected by Codiak BioSciences to support its cleanroom build out at its new clinical manufacturing ...
Read More »Sarepta Therapeutics and Codiak Biosciences collaborate to research and develop exosome-based therapeutics for rare diseases
Alliance to explore the utility of engineered exosomes developed with Codiak’s engEx™ Platform to deliver gene therapy, gene editing and RNA technologies – – Two-year, global research and option...
Read More »Codiak BioSciences Collaborates with Ragon Institute to evaluate the exoVACC™ vaccine platform in SARS-CoV-2 and HIV
Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the ...
Read More »Codiak presents new preclinical data demonstrating potential of engEx™ engineered exosomes to drive new class of molecular medicines
Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced new preclinical...
Read More »Codiak Presents New Preclinical Data for First-in-Class Exosome Therapeutic Candidates, exoIL-12 and exoSTING, Demonstrating Potent Anti-Tumor Activity
exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12 exoSTING shows unique pharmacodynamic effects and tumor antigen-specific systemic immune responses.
Read More »Development Update – Codiak’s engEx platform for engineered exosomes and therapeutic potential of exoSTING
In vitro and in vivo profile of exoSTING showed greater potency, preservation of T cells and APCs, greater systemic tumor antigen specific immune response, reduced systemic cytokine production, and enhanced anti-tumor immunity compared to free STING agonist Codiak’s PTGFRN ...
Read More »Jazz Pharmaceuticals and Codiak BioSciences Announce $1B Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes
Collaboration strengthens Jazz portfolio with novel therapeutic approach that has potential to provide transformational benefit to subgroup of patients with modulations in well validated but previously...
Read More »Codiak BioSciences Closes $76.5 Million Series C Financing
Proceeds Will Carry First Drug Candidates Into Clinical Trials. Existing And New Investors Participate Codiak BioSciences, Inc., the leading exosome therapeutics company, today announced the...
Read More »Featured Exosome Job – Director, Oncology
Director, Oncology (ref#CB-1010) Cambridge, MA – March 14, 2017 – Codiak POSITION DESCRIPTION Codiak BioSciences is seeking an experienced professional to lead the oncology/immuno-oncology programs at Codiak. The Director, Oncology will have extensive experience with in vitro and in vivo ...
Read More »